Resources

Past Presentation

Residual Risk for HCC in Patients After HCV SVR | February 23, 2022

Date of Presentation: February 23, 2022

Type: Past Presentation  

Audience: Clinical  

Program: Hepatitis C  

Keywords: #cure  #hcc  #hepatocellular carcinoma  #svr  

In this presentation, Dr. Raymond Chung, 2021 AASLD President and Director of Hepatology and the Liver Center at Massachusetts General Hospital, discusses the residual risk for hepatocellular carcinoma in patients after achieving cure from hepatitis C virus.

Recording:

Presented by:

Dr Raymond Chung

Raymond Chung, MD, is Director of Hepatology and the Liver Center at Massachusetts General Hospital, Vice Chief of Gastroenterology, and Kevin and Polly Maroni MGH Research Scholar. In 2021, he will serve as President of the American Association for the Study of Liver Diseases. Dr. Chung completed his B.A. at Harvard College and his MD from Yale University School of Medicine. He completed a residency in Internal Medicine at Johns Hopkins and a fellowship in Gastroenterology and Hepatology at Massachusetts General Hospital.

Dr. Chung has been internationally recognized for his fundamental and translational research in viral hepatitis, particularly in HCV and HBV infection. His laboratory has elucidated the basis for the observed accelerated liver disease pathogenesis in persons with HIV.  He has also led important work defining biomarkers and gene signatures for persons at high risk for liver disease progression and liver cancer, and designed therapeutic studies to prevent this progression.

Resources Provided:

Date added: February 22, 2022